Empagliflozin Repurposing for Lafora Disease: A Pilot Clinical Trial and Preclinical Investigation of Novel Therapeutic Targets
The findings of this study are expected to provide evidence in support of the repurposing of empagliflozin for the treatment of LD.
Authors
- Nicola Gambacorta (ORCID: https://orcid.org/0000-0003-1965-1519)
- Paola Imbrici (ORCID: https://orcid.org/0000-0001-9140-5350)
- Massimo Carella (ORCID: https://orcid.org/0000-0002-6830-6829)
- Antonella Liantonio (ORCID: https://orcid.org/0000-0002-4103-7577)
- G. D’Orsi (ORCID: https://orcid.org/0000-0002-3465-7540)
- Cosimo Altomare (ORCID: https://orcid.org/0000-0001-5016-5805)
- Giorgia Dinoi (ORCID: https://orcid.org/0009-0007-9250-5610)
- DEFEAT-LD Study Group DEFEAT-LD Study Group
Institutions
- Casa Sollievo della Sofferenza (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Methods and Protocols
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3390/mps8030048
- Citations
- 2
- Primary Topic
- Glycogen Storage Diseases and Myoclonus
- Type
- article
- Field-Weighted Citation Impact
- 3.34